Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions
TreatmentPeripheral T-cell Lymphoma
Interventions
DRUG

liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin

"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."

Trial Locations (5)

Unknown

NOT_YET_RECRUITING

Beijing Hospital, Beijing

NOT_YET_RECRUITING

Beijing Luhe Hospital, Capital Medical University, Beijing

NOT_YET_RECRUITING

China-Japan Friendship Hospital, Beijing

RECRUITING

Peking Union Medical College Hospital, Beijing

NOT_YET_RECRUITING

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER